Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | APEX1 | P27695 | 3/20 | 0.69 |
| ▸ | RECQL | P46063 | 3/20 | 0.69 |
| ▸ | SNCA | P37840 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.69 |
| ▸ | ALPL | P05186 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | RAD52 | P43351 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862104 | 1.00 | BACE1 (0.69) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL31028352 | 1.00 | BACE1 (0.69) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL5924559 | 1.00 | BACE1 (0.69) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL348596 | 0.94 | BACE1 (0.74) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL30843342 | 0.94 | BACE1 (0.74) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL29934352 | 0.94 | BACE1 (0.74) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL348595 | 0.94 | BACE1 (0.74) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| SCHEMBL349872 | 0.94 | BACE1 (0.74) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| 3'-O-Methyl Epicatechin SCHEMBL25248714 | 0.93 | BACE1 (0.73) | BACE1KDM4EPTGS1MAPTCYP3A4 | |
| 3'-O-Methyl Epicatechin SCHEMBL30933002 | 0.93 | BACE1 (0.73) | BACE1KDM4EPTGS1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180209956-A1 | HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-07-26 | — | — | US | claimed |
| WO-2017015187-A1 | HIGH THROUGHPUT SCREENING ASSAY FOR IDENTIFYING INHIBITORS OF RAD52 AND USES OF THE IDENTIFIED INHIBITORS FOR TREATMENT AND/OR PREVENTION OF MALIGNACIES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-01-26 | — | — | WO | claimed |
| US-20180209956-A1 | HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2017015187-A1 | HIGH THROUGHPUT SCREENING ASSAY FOR IDENTIFYING INHIBITORS OF RAD52 AND USES OF THE IDENTIFIED INHIBITORS FOR TREATMENT AND/OR PREVENTION OF MALIGNACIES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-01-26 | — | — | WO | disclosed |
| EP-1898902-A2 | COMPOSITIONS AND METHODS OF USE OF DERIVATIZED FLAVANOLS | Mars, Incorporated (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002881-A2 | COMPOSITIONS AND METHODS OF USE OF DERIVATIZED FLAVANOLS | MARS, INCORPORATED (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293259-A1 | Compositions and methods of use of derivatized flavanols | MARS, INCORPORATED (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293259-A1 | Compositions and methods of use of derivatized flavanols | F2, PIGS, PIGO | BACE1 4677/4885KDM4E 428/4885PTGS1 358/4885 |
| US-20180209956-A1 | HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies | RAD52, BRCA1, RAD50 | BACE1 3735/4885KDM4E 3907/4885PTGS1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.